MeSH term
Frequency | Condition_Probility | Antigens, CD/metabolism | 33 | 3.0 |
Basophils/*immunology | 9 | 42.0 |
Female | 153 | 0.0 |
Flow Cytometry/methods | 9 | 3.0 |
Histamine Release | 11 | 18.0 |
Humans | 408 | 0.0 |
Immunoglobulin E/blood | 5 | 3.0 |
Male | 144 | 0.0 |
Phosphoric Diester Hydrolases/*metabolism | 2 | 8.0 |
Platelet Membrane Glycoproteins/metabolism | 29 | 35.0 |
Poaceae/immunology | 2 | 18.0 |
Pyrophosphatases/*metabolism | 2 | 28.0 |
Research Support, Non-U.S. Gov't | 254 | 0.0 |
Up-Regulation | 9 | 0.0 |
Aged | 79 | 0.0 |
Antigens, CD/analysis | 37 | 2.0 |
Epitopes | 3 | 0.0 |
Middle Aged | 113 | 0.0 |
P-Selectin/analysis | 7 | 35.0 |
*Platelet Activation | 44 | 31.0 |
Platelet Membrane Glycoproteins/analysis | 36 | 52.0 |
Adult | 128 | 0.0 |
Biological Markers/analysis | 12 | 1.0 |
Flow Cytometry | 102 | 1.0 |
Immunohistochemistry | 30 | 0.0 |
Monocytes/*metabolism | 2 | 0.0 |
Animals | 79 | 0.0 |
Centrifugation, Density Gradient | 2 | 0.0 |
Comparative Study | 65 | 0.0 |
Histamine Release/drug effects | 2 | 8.0 |
Immunoglobulin E/immunology | 3 | 5.0 |
Phenotype | 9 | 0.0 |
Rats | 10 | 0.0 |
Genes, Dominant | 2 | 0.0 |
Hela Cells | 9 | 0.0 |
Tetradecanoylphorbol Acetate/*pharmacology | 2 | 0.0 |
Tissue Distribution | 4 | 0.0 |
Transfection | 14 | 0.0 |
Cell Line | 37 | 0.0 |
Fetal Blood/cytology | 2 | 1.0 |
*Membrane Glycoproteins | 22 | 2.0 |
Membrane Proteins/*metabolism/physiology | 2 | 22.0 |
Multigene Family | 2 | 0.0 |
Phosphorylation/drug effects | 2 | 0.0 |
Precipitin Tests | 12 | 0.0 |
Protein Binding/drug effects | 3 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 54 | 0.0 |
*Apoptosis | 2 | 0.0 |
Blotting, Western | 11 | 0.0 |
Exocytosis | 3 | 4.0 |
Intracellular Membranes/metabolism | 3 | 1.0 |
Jurkat Cells | 2 | 0.0 |
Membrane Glycoproteins/immunology/*metabolism | 2 | 4.0 |
Microscopy, Electron | 18 | 0.0 |
Tumor Cells, Cultured | 32 | 0.0 |
Antigens, CD/*blood | 13 | 7.0 |
Asthma/blood | 2 | 18.0 |
Cell Adhesion Molecules/*blood | 4 | 6.0 |
Enzyme Inhibitors/pharmacology | 6 | 0.0 |
Eosinophils/*physiology | 2 | 4.0 |
Microscopy, Confocal | 10 | 1.0 |
Microscopy, Fluorescence | 2 | 0.0 |
Platelet Membrane Glycoproteins | 18 | 39.0 |
RANTES/blood | 2 | 18.0 |
Blood Platelets/drug effects/*metabolism | 4 | 5.0 |
Enzyme-Linked Immunosorbent Assay | 8 | 0.0 |
P-Selectin/metabolism | 14 | 29.0 |
Platelet Aggregation/drug effects | 12 | 5.0 |
Platelet Glycoprotein GPIIb-IIIa Complex/metabolism | 10 | 25.0 |
von Willebrand Factor/metabolism | 2 | 0.0 |
Antigens, CD/*metabolism | 23 | 3.0 |
Antigens, Differentiation, T-Lymphocyte/*metabolism | 2 | 1.0 |
Biological Markers | 18 | 1.0 |
Blood Cells/metabolism | 2 | 6.0 |
Time Factors | 28 | 0.0 |
Blood Platelets/*chemistry/ultrastructure | 3 | 75.0 |
Cell Fractionation | 2 | 0.0 |
Cytoplasmic Granules/*chemistry | 3 | 17.0 |
Basophils/drug effects/*metabolism | 2 | 33.0 |
Macrophage-1 Antigen/metabolism | 3 | 4.0 |
Respiratory Burst | 2 | 3.0 |
Acute Disease | 5 | 0.0 |
Adenosine Diphosphate/pharmacology | 12 | 10.0 |
Aged, 80 and over | 17 | 0.0 |
Blood Platelets/drug effects/*physiology | 4 | 9.0 |
P-Selectin/blood | 24 | 39.0 |
Platelet Activation/drug effects | 9 | 15.0 |
Platelet Function Tests/methods | 2 | 40.0 |
Receptors, Thrombin/physiology | 2 | 25.0 |
Antigens, CD/blood | 18 | 7.0 |
Antigens, CD31/blood | 3 | 33.0 |
Aspirin/pharmacology/*therapeutic use | 2 | 50.0 |
CD40 Ligand/blood | 3 | 50.0 |
Platelet Aggregation/*drug effects | 4 | 3.0 |
Platelet Aggregation Inhibitors/pharmacology/*therapeutic use | 2 | 40.0 |
Platelet Function Tests | 7 | 17.0 |
Platelet Membrane Glycoprotein IIb/blood | 3 | 75.0 |
Treatment Outcome | 4 | 0.0 |
CHO Cells | 4 | 0.0 |
Detergents | 3 | 2.0 |
Hamsters | 7 | 0.0 |
In Vitro | 28 | 0.0 |
Macromolecular Substances | 5 | 0.0 |
Membrane Proteins/chemistry/genetics/*metabolism | 2 | 3.0 |
Mutagenesis, Site-Directed | 3 | 0.0 |
Antigens, CD/*analysis | 21 | 2.0 |
Basophils/*physiology | 4 | 33.0 |
Immunoglobulin E/analysis | 6 | 11.0 |
Platelet Membrane Glycoproteins/*analysis | 14 | 43.0 |
Reference Values | 15 | 0.0 |
Sensitivity and Specificity | 15 | 0.0 |
Skin Tests | 7 | 3.0 |
Antigens, CD/*analysis/immunology | 3 | 10.0 |
Blood Platelets/*immunology | 7 | 8.0 |
*Platelet Aggregation | 4 | 4.0 |
Antigens, CD/genetics/*metabolism | 5 | 5.0 |
Cell Separation | 8 | 0.0 |
Lysosomes/*metabolism | 3 | 3.0 |
Platelet Membrane Glycoproteins/genetics/*metabolism | 2 | 25.0 |
Amino Acid Sequence | 23 | 0.0 |
Biological Transport/physiology | 2 | 1.0 |
Brefeldin A/pharmacology | 3 | 3.0 |
Molecular Sequence Data | 28 | 0.0 |
Protein Synthesis Inhibitors/pharmacology | 3 | 0.0 |
Recombinant Fusion Proteins/metabolism | 2 | 0.0 |
Sequence Alignment | 4 | 0.0 |
Cell Membrane/metabolism | 7 | 0.0 |
Cytoplasm/metabolism | 3 | 0.0 |
Cytosol/metabolism | 2 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 3 | 0.0 |
Heterozygote | 2 | 0.0 |
Immunoblotting | 5 | 0.0 |
Models, Biological | 7 | 0.0 |
Mutation | 2 | 0.0 |
Plasmids/metabolism | 2 | 0.0 |
Protein Structure, Tertiary | 5 | 0.0 |
Antigens, CD45/metabolism | 2 | 2.0 |
Antigens, Surface/*metabolism | 3 | 5.0 |
Apoptosis | 3 | 0.0 |
Intercellular Adhesion Molecule-1/metabolism | 2 | 1.0 |
*Respiratory Burst | 2 | 10.0 |
Adolescent | 19 | 0.0 |
Case-Control Studies | 16 | 0.0 |
Child | 14 | 0.0 |
Immunophenotyping | 18 | 0.0 |
Kinetics | 7 | 0.0 |
Platelet Activation/*drug effects | 16 | 25.0 |
Swine | 4 | 0.0 |
English Abstract | 26 | 0.0 |
Germany | 2 | 0.0 |
Antigens, CD/*immunology | 7 | 1.0 |
Platelet Membrane Glycoproteins/*immunology | 7 | 24.0 |
Antigens, CD/analysis/immunology | 2 | 4.0 |
COS Cells | 4 | 0.0 |
Cercopithecus aethiops | 5 | 0.0 |
Lymphocyte Activation/*immunology | 2 | 0.0 |
Mice | 26 | 0.0 |
Mice, Inbred BALB C | 7 | 0.0 |
Mice, Inbred C57BL | 4 | 0.0 |
Signal Transduction/*immunology | 2 | 0.0 |
HLA-DR Antigens/metabolism | 3 | 2.0 |
Integrins/analysis | 4 | 8.0 |
Interferon Type II/pharmacology | 4 | 0.0 |
Transcription, Genetic | 7 | 0.0 |
Basophils/*immunology/metabolism | 2 | 66.0 |
*Up-Regulation | 2 | 0.0 |
Cloning, Molecular | 12 | 0.0 |
Ligands | 2 | 0.0 |
Pregnancy | 11 | 0.0 |
Protein Binding | 10 | 0.0 |
Fluorescent Antibody Technique | 9 | 0.0 |
Receptors, IgG/physiology | 2 | 5.0 |
Blood Platelets/immunology | 6 | 8.0 |
Platelet Count/*methods | 2 | 66.0 |
Cytochalasin B/pharmacology | 4 | 4.0 |
Membrane Proteins/metabolism | 7 | 1.0 |
Platelet Activation/*physiology | 18 | 31.0 |
Thrombin/pharmacology/physiology | 2 | 66.0 |
Blood Platelets/*metabolism | 14 | 5.0 |
Cell Adhesion Molecules/blood | 8 | 25.0 |
Diagnosis, Differential | 3 | 0.0 |
*Medicine, Chinese Traditional | 2 | 8.0 |
P-Selectin/*blood | 9 | 27.0 |
Cell Adhesion/drug effects | 3 | 0.0 |
Dose-Response Relationship, Drug | 9 | 0.0 |
Androstadienes/pharmacology | 4 | 1.0 |
Biological Transport | 6 | 0.0 |
Lysosomes/physiology | 3 | 33.0 |
*Oxidoreductases | 3 | 3.0 |
Proteins/*metabolism | 2 | 0.0 |
Drug Interactions | 3 | 0.0 |
Platelet Adhesiveness/drug effects | 2 | 4.0 |
Platelet Glycoprotein GPIIb-IIIa Complex/drug effects/metabolism | 2 | 66.0 |
Platelet Membrane Glycoproteins/*drug effects/metabolism | 2 | 100.0 |
Blood Platelets/metabolism/*ultrastructure | 3 | 60.0 |
Platelet Membrane Glycoproteins/*metabolism | 18 | 16.0 |
Antigens, Surface/metabolism | 3 | 2.0 |
Cell Adhesion | 6 | 0.0 |
Cell Adhesion Molecules/*metabolism | 4 | 1.0 |
Cells, Cultured | 25 | 0.0 |
Cytokines/metabolism | 2 | 0.0 |
Stress, Mechanical | 3 | 1.0 |
*Stents | 2 | 3.0 |
Heart Transplantation | 2 | 5.0 |
Infusions, Intravenous | 3 | 0.0 |
Exocytosis/physiology | 3 | 13.0 |
Histocompatibility Antigens Class II/analysis | 2 | 1.0 |
Microscopy, Immunoelectron | 13 | 2.0 |
Receptors, Transferrin/analysis | 2 | 5.0 |
Anticoagulants/pharmacology | 4 | 5.0 |
Biological Markers/blood | 19 | 1.0 |
Flow Cytometry/*methods | 15 | 6.0 |
Specimen Handling | 2 | 2.0 |
Base Sequence | 20 | 0.0 |
DNA Primers | 2 | 0.0 |
Integrin alpha3beta1 | 8 | 25.0 |
Integrins/*metabolism | 7 | 4.0 |
Membrane Proteins/*metabolism | 7 | 1.0 |
Autoimmune Diseases/*immunology | 2 | 1.0 |
Chronic Disease | 4 | 0.0 |
Skin Tests/methods | 2 | 20.0 |
Allergens/*immunology | 3 | 3.0 |
Antigens, CD/*biosynthesis | 9 | 4.0 |
Antigens, Dermatophagoides | 2 | 3.0 |
Basophil Degranulation Test | 2 | 33.0 |
Glycoproteins/*immunology | 2 | 2.0 |
Histamine Release/immunology | 4 | 40.0 |
Platelet Membrane Glycoproteins/*biosynthesis | 7 | 63.0 |
Wasp Venoms/*immunology | 2 | 66.0 |
Cell Division | 5 | 0.0 |
Phagocytosis | 3 | 0.0 |
Actins/metabolism | 4 | 0.0 |
Calcium-Binding Proteins/metabolism | 2 | 2.0 |
Neoplasm Proteins/metabolism | 2 | 0.0 |
Dose-Response Relationship, Immunologic | 3 | 0.0 |
Pollen/*adverse effects | 2 | 66.0 |
Blood Circulation | 2 | 10.0 |
Collagen/pharmacology | 7 | 5.0 |
Infant, Newborn/*blood | 2 | 4.0 |
Platelet Activation | 20 | 14.0 |
Ristocetin/pharmacology | 3 | 2.0 |
Antigens, CD/*genetics | 6 | 2.0 |
Membrane Glycoproteins/*genetics | 4 | 0.0 |
Platelet Membrane Glycoproteins/genetics | 2 | 15.0 |
Blood Platelets/*drug effects/metabolism | 3 | 8.0 |
Calcimycin/pharmacology | 2 | 0.0 |
Calcium/blood | 2 | 0.0 |
Cytoplasmic Granules/chemistry | 3 | 15.0 |
Gene Expression Regulation/drug effects | 2 | 0.0 |
Ionophores/pharmacology | 2 | 1.0 |
Peptide Fragments/pharmacology | 6 | 2.0 |
Platelet Aggregation Inhibitors/*pharmacology | 5 | 7.0 |
Tetradecanoylphorbol Acetate/pharmacology | 4 | 0.0 |
Thrombin/pharmacology | 8 | 3.0 |
Antigens, CD/biosynthesis | 5 | 1.0 |
Antigens, Differentiation/biosynthesis | 2 | 3.0 |
Cell Differentiation | 3 | 0.0 |
*Neutrophil Activation | 6 | 19.0 |
Statistics, Nonparametric | 4 | 0.0 |
Antibodies, Monoclonal | 19 | 0.0 |
Cytoplasmic Granules/metabolism/ultrastructure | 3 | 30.0 |
Platelet Activation/drug effects/*physiology | 5 | 29.0 |
Platelet Glycoprotein GPIIb-IIIa Complex/*metabolism | 3 | 10.0 |
Antibodies, Monoclonal/diagnostic use | 3 | 0.0 |
Antigens, CD29/analysis | 2 | 9.0 |
Antigens, Surface/*analysis | 3 | 1.0 |
Cell Adhesion Molecules/analysis | 6 | 3.0 |
Image Processing, Computer-Assisted | 2 | 0.0 |
Immunoenzyme Techniques | 3 | 0.0 |
Endothelium, Vascular/cytology/*metabolism | 2 | 1.0 |
*Exocytosis | 3 | 10.0 |
Lysosomes/metabolism | 4 | 2.0 |
P-Selectin/*metabolism | 5 | 23.0 |
Protein Transport | 4 | 0.0 |
*Endocytosis | 4 | 2.0 |
Endosomes/metabolism/microbiology | 2 | 100.0 |
Phagosomes/metabolism/microbiology | 2 | 66.0 |
Receptors, Transferrin/metabolism | 3 | 4.0 |
Endocytosis | 3 | 0.0 |
Cell Adhesion Molecules/immunology/metabolism | 2 | 25.0 |
Histocompatibility Antigens Class II/*metabolism | 2 | 3.0 |
Calcium/metabolism | 5 | 0.0 |
K562 Cells | 2 | 0.0 |
Staining and Labeling/methods | 2 | 1.0 |
*Hemostasis | 2 | 1.0 |
Platelet Aggregation | 4 | 2.0 |
Prospective Studies | 7 | 0.0 |
*Membrane Proteins | 11 | 1.0 |
Bee Venoms/*immunology | 2 | 28.0 |
Hymenoptera/*immunology | 2 | 50.0 |
Platelet Glycoprotein GPIIb-IIIa Complex/*antagonists & inhibitors | 2 | 10.0 |
Analysis of Variance | 5 | 0.0 |
Blood Platelets/drug effects/metabolism | 2 | 4.0 |
Platelet Aggregation Inhibitors/*therapeutic use | 4 | 16.0 |
Platelet Count | 13 | 2.0 |
Platelet Glycoprotein GPIIb-IIIa Complex/analysis | 8 | 33.0 |
Blood Platelets/chemistry | 4 | 13.0 |
Blood Preservation | 6 | 8.0 |
Edetic Acid/pharmacology | 3 | 1.0 |
False Positive Reactions | 3 | 1.0 |
Flow Cytometry/*methods/standards | 2 | 28.0 |
Platelet Glycoprotein GPIb-IX Complex/metabolism | 10 | 18.0 |
Receptors, Thrombin | 2 | 4.0 |
Temperature | 3 | 0.0 |
Antigens, CD/immunology/metabolism | 3 | 5.0 |
*Flow Cytometry | 8 | 4.0 |
Hymenoptera | 2 | 50.0 |
Hypersensitivity/*diagnosis/immunology | 3 | 100.0 |
Statistics | 3 | 0.0 |
Membrane Glycoproteins/*metabolism | 4 | 0.0 |
Filtration | 2 | 4.0 |
Plateletpheresis/*methods | 2 | 66.0 |
Biocompatible Materials | 2 | 3.0 |
Blood Cell Count | 2 | 0.0 |
Cross-Over Studies | 2 | 0.0 |
Materials Testing | 2 | 2.0 |
*Membranes, Artificial | 2 | 2.0 |
Evaluation Studies | 2 | 0.0 |
Leukocyte Count | 8 | 0.0 |
*Leukocytes | 3 | 15.0 |
Cell Adhesion/physiology | 2 | 0.0 |
Proto-Oncogene Proteins/metabolism | 2 | 0.0 |
Neutrophils/*immunology | 5 | 2.0 |
Annexin A5/*metabolism | 2 | 22.0 |
Aspirin/pharmacology | 2 | 3.0 |
Dipyridamole/pharmacology | 3 | 21.0 |
Heparin/pharmacology | 3 | 1.0 |
Platelet Aggregation Inhibitors/pharmacology | 4 | 6.0 |
Cell Adhesion Molecules/metabolism | 6 | 2.0 |
Down-Regulation | 8 | 0.0 |
Receptors, Cell Surface/metabolism | 2 | 0.0 |
Dogs | 3 | 0.0 |
Double-Blind Method | 2 | 0.0 |
Cell Communication | 4 | 1.0 |
T-Lymphocytes/immunology | 4 | 0.0 |
CD40 Ligand | 2 | 1.0 |
Cytokines/*blood | 2 | 0.0 |
Fibrinogen/metabolism | 7 | 3.0 |
Membrane Glycoproteins/blood | 4 | 13.0 |
Solubility | 4 | 0.0 |
Binding Sites | 6 | 0.0 |
L Cells (Cell Line) | 2 | 0.0 |
Membrane Glycoproteins/metabolism | 9 | 1.0 |
*Proto-Oncogene Proteins | 9 | 0.0 |
Structure-Activity Relationship | 3 | 0.0 |
Annexin A5/metabolism | 3 | 3.0 |
Cell Membrane/drug effects/metabolism | 2 | 2.0 |
Fluorescence | 2 | 0.0 |
Up-Regulation/drug effects | 2 | 0.0 |
Fibrinogen/*metabolism | 3 | 4.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 9 | 0.0 |
Antigens, CD11/*metabolism | 2 | 50.0 |
Antigens, CD18/*metabolism | 2 | 10.0 |
Cell Membrane/immunology | 4 | 1.0 |
Child, Preschool | 8 | 0.0 |
Infant | 3 | 0.0 |
Angioplasty, Transluminal, Percutaneous Coronary | 2 | 4.0 |
B-Lymphocytes | 2 | 1.0 |
Basophils/immunology | 2 | 10.0 |
Drug Hypersensitivity/*diagnosis | 2 | 50.0 |
*Histamine Release | 2 | 16.0 |
Adenosine/pharmacology | 2 | 8.0 |
Antigens, CD/analysis/*blood | 2 | 40.0 |
Blood Platelets/*physiology | 4 | 2.0 |
*Platelet Activation/drug effects | 5 | 35.0 |
Theophylline/pharmacology | 2 | 5.0 |
Blood Platelets/physiology/*ultrastructure | 2 | 50.0 |
Cell Degranulation | 7 | 16.0 |
Cytoplasmic Granules/physiology/*ultrastructure | 2 | 40.0 |
Receptors, Thrombin/agonists/physiology | 2 | 100.0 |
Blood Glucose/metabolism | 2 | 0.0 |
Diabetic Angiopathies/*blood | 2 | 9.0 |
Hemoglobin A, Glycosylated/metabolism | 2 | 1.0 |
*Blood Platelets | 2 | 9.0 |
*Blood Preservation | 6 | 10.0 |
Fibrinogen/analysis | 4 | 2.0 |
Antigens, CD/*physiology | 4 | 1.0 |
Antigens, Human Platelet/*immunology | 2 | 18.0 |
Thrombocytopenia/immunology | 2 | 22.0 |
P-Selectin/*analysis | 2 | 50.0 |
Microscopy, Electron, Scanning | 3 | 1.0 |
Proteins/metabolism | 3 | 0.0 |
Rabbits | 4 | 0.0 |
Infant, Newborn | 2 | 0.0 |
Antigens, Surface/analysis | 4 | 0.0 |
Neutrophils/*immunology/secretion | 2 | 100.0 |
Allergens/immunology | 3 | 4.0 |
Glycoproteins/immunology | 2 | 2.0 |
Hypersensitivity/*diagnosis | 2 | 33.0 |
Antigen-Presenting Cells/immunology | 2 | 0.0 |
Antigens, CD/immunology | 7 | 1.0 |
Antigens, CD3/immunology | 2 | 0.0 |
Epithelial Cells/immunology | 2 | 5.0 |
Membrane Glycoproteins/immunology | 3 | 1.0 |
Receptors, IgG/metabolism | 2 | 2.0 |
Reverse Transcriptase Polymerase Chain Reaction | 2 | 0.0 |
Reproducibility of Results | 5 | 0.0 |
Drug Synergism | 2 | 0.0 |
Drug Therapy, Combination | 5 | 0.0 |
Gene Expression Profiling | 2 | 0.0 |
Gene Library | 3 | 0.0 |
Oligonucleotide Array Sequence Analysis | 2 | 0.0 |
Phosphorylation | 5 | 0.0 |
Protein-Tyrosine Kinase/metabolism | 2 | 0.0 |
*Signal Transduction | 3 | 0.0 |
Odds Ratio | 2 | 0.0 |
Risk Factors | 8 | 0.0 |
Blood Donors | 3 | 1.0 |
Enzyme-Linked Immunosorbent Assay/methods | 2 | 0.0 |
Monocytes/*immunology | 2 | 0.0 |
*Anticoagulants | 2 | 16.0 |
Citrates/pharmacology | 3 | 16.0 |
Platelet Glycoprotein GPIb-IX Complex/analysis | 3 | 17.0 |
Antibody Specificity | 4 | 0.0 |
*Cold | 2 | 3.0 |
Blotting, Northern | 3 | 0.0 |
Gene Expression Regulation | 3 | 0.0 |
Blood Platelets/metabolism | 4 | 2.0 |
P-Selectin/*biosynthesis | 2 | 25.0 |
Stents/*adverse effects | 2 | 6.0 |
Antibodies, Monoclonal/immunology | 9 | 0.0 |
Antigens, CD/immunology/*metabolism | 4 | 8.0 |
Epitopes/immunology | 3 | 0.0 |
Integrin alpha6beta1 | 2 | 10.0 |
Molecular Weight | 3 | 0.0 |
Antibodies, Monoclonal/metabolism | 2 | 0.0 |
von Willebrand Disease/*blood | 2 | 5.0 |
N-Formylmethionine Leucyl-Phenylalanine/pharmacology | 4 | 1.0 |
Platelet Activation/physiology | 3 | 10.0 |
*Antigens, CD | 5 | 0.0 |
Antigens, CD/*analysis/physiology | 2 | 16.0 |
Cell Movement | 3 | 0.0 |
Perfusion | 2 | 0.0 |
Selectins/metabolism | 2 | 25.0 |
Basophils/*immunology/physiology | 3 | 100.0 |
Antigens, CD/*analysis/genetics | 3 | 12.0 |
Platelet Membrane Glycoproteins/*analysis/genetics | 3 | 100.0 |
Antibodies, Monoclonal/pharmacology | 3 | 0.0 |
Cell Adhesion/immunology | 2 | 1.0 |
Tyrosine/metabolism | 3 | 0.0 |
Thrombosis/etiology | 3 | 4.0 |
Fluorescein-5-isothiocyanate | 3 | 2.0 |
Fluorescent Dyes | 2 | 0.0 |
*Renal Dialysis | 5 | 1.0 |
Mast Cells/*metabolism | 2 | 5.0 |
Leukocytes/physiology | 2 | 3.0 |
Platelet Activation/*immunology | 4 | 22.0 |
Cell Degranulation/*drug effects | 3 | 16.0 |
Ethanol/*pharmacology | 2 | 1.0 |
Solvents/*pharmacology | 2 | 20.0 |
Thrombin/*pharmacology | 2 | 1.0 |
Hydrogen-Ion Concentration | 3 | 0.0 |
Probability | 2 | 0.0 |
Radioimmunoassay | 2 | 0.0 |
Receptors, IgG/biosynthesis | 2 | 7.0 |
Cell Line, Transformed | 2 | 0.0 |
Leukocytes/*immunology | 2 | 1.0 |
Gene Expression | 7 | 0.0 |
Membrane Proteins/*genetics | 2 | 0.0 |
Polymerase Chain Reaction | 9 | 0.0 |
Translocation, Genetic | 2 | 0.0 |
Anticoagulants/therapeutic use | 2 | 2.0 |
Aspirin/therapeutic use | 2 | 5.0 |
Platelet Aggregation Inhibitors/therapeutic use | 2 | 7.0 |
Antiphospholipid Syndrome/*blood/complications | 2 | 50.0 |
HLA-D Antigens/metabolism | 2 | 11.0 |
Cell Differentiation/drug effects | 3 | 0.0 |
Dimethyl Sulfoxide/*pharmacology | 2 | 8.0 |
Cell Adhesion Molecules/immunology | 2 | 2.0 |
Platelet Membrane Glycoproteins/immunology | 5 | 27.0 |
Disease Progression | 3 | 0.0 |
Sequence Analysis, DNA | 2 | 0.0 |
Sequence Homology, Amino Acid | 6 | 0.0 |
*Antigen Presentation | 2 | 1.0 |
Cell Compartmentation | 3 | 0.0 |
Membrane Fusion | 3 | 2.0 |
Cell Size | 3 | 1.0 |
Signal Transduction | 3 | 0.0 |
Antigens, CD/biosynthesis/*genetics | 3 | 11.0 |
Platelet Membrane Glycoproteins/biosynthesis/*genetics | 3 | 50.0 |
*Cardiopulmonary Bypass | 2 | 2.0 |
Protein-Tyrosine-Phosphatase/metabolism | 2 | 1.0 |
DNA, Complementary | 3 | 0.0 |
RNA, Messenger/analysis | 3 | 0.0 |
Antigens, Human Platelet/analysis | 3 | 60.0 |
Centrifugation | 3 | 4.0 |
Antigens, CD/drug effects | 2 | 28.0 |
Aspirin/*therapeutic use | 4 | 25.0 |
Cohort Studies | 2 | 0.0 |
Epinephrine/pharmacology | 3 | 3.0 |
P-Selectin/blood/drug effects | 2 | 100.0 |
Platelet Glycoprotein GPIIb-IIIa Complex/drug effects | 2 | 100.0 |
Cell Line, Tumor | 3 | 0.0 |
Melanins/*metabolism | 2 | 13.0 |
Oligosaccharides, Branched-Chain/*metabolism | 2 | 100.0 |
Antigens, CD/genetics/*immunology | 3 | 8.0 |
Melanoma/*immunology | 2 | 2.0 |
Platelet Membrane Glycoproteins/genetics/*immunology | 2 | 66.0 |
Antigens, CD14/analysis | 2 | 1.0 |
Antigens, CD45/analysis | 2 | 0.0 |
Basophils/cytology/*immunology | 2 | 66.0 |
Lymphocyte Activation | 4 | 0.0 |
Cattle | 4 | 0.0 |
Histocompatibility Antigens Class I/metabolism | 2 | 3.0 |
Antibodies/pharmacology | 2 | 0.0 |
Cycloheximide/pharmacology | 2 | 0.0 |
Fluorescent Antibody Technique, Indirect | 4 | 0.0 |
Platelet Membrane Glycoproteins/physiology | 2 | 11.0 |
Integrin beta3/metabolism | 2 | 18.0 |
Pre-Eclampsia/*blood | 5 | 10.0 |
Pregnancy/*blood | 2 | 1.0 |
Integrins/immunology | 3 | 14.0 |
Platelet Membrane Glycoproteins/*physiology | 2 | 6.0 |
*Antigens, Neoplasm | 7 | 3.0 |
Cell Communication/immunology | 2 | 2.0 |
Antigens, Neoplasm/analysis | 2 | 0.0 |
Chromosome Banding | 2 | 0.0 |
DNA, Viral/analysis | 2 | 0.0 |
Karyotyping | 2 | 0.0 |
Antigens, CD29/*metabolism | 2 | 5.0 |
Biological Markers/*blood | 2 | 1.0 |
Antigens, Human Platelet/*blood | 2 | 66.0 |
Follow-Up Studies | 6 | 0.0 |
Triglycerides/blood | 2 | 0.0 |
Rheology | 2 | 2.0 |
Signal Transduction/physiology | 2 | 0.0 |
Antigens, CD36/metabolism | 2 | 4.0 |
Staining and Labeling | 4 | 0.0 |
Antibodies, Monoclonal/*chemistry | 2 | 5.0 |
Cross Reactions | 4 | 0.0 |
P-Selectin/immunology | 2 | 40.0 |
*Multigene Family | 3 | 0.0 |
Autoantibodies/blood | 2 | 1.0 |
Risk Assessment | 2 | 0.0 |
Thrombospondins | 6 | 5.0 |
HLA Antigens/analysis | 3 | 1.0 |
*Immunophenotyping | 3 | 1.0 |
DNA, Neoplasm/analysis | 2 | 0.0 |
Binding Sites, Antibody/immunology | 2 | 13.0 |
Platelet Glycoprotein GPIIb-IIIa Complex/immunology | 2 | 18.0 |
Chromones/pharmacology | 2 | 0.0 |
Morpholines/pharmacology | 2 | 0.0 |
Anticoagulants/*pharmacology | 2 | 2.0 |
Asthma/*immunology | 2 | 2.0 |
HLA-DR Antigens/analysis | 2 | 0.0 |
Pedigree | 2 | 0.0 |
Regression Analysis | 2 | 0.0 |
Blood Preservation/*methods | 3 | 13.0 |
P-Selectin/*immunology | 2 | 40.0 |
Antigens, CD/*chemistry | 2 | 7.0 |
Membrane Glycoproteins/*chemistry | 2 | 6.0 |
Coronary Angiography | 2 | 0.0 |
*Angioplasty, Transluminal, Percutaneous Coronary | 2 | 4.0 |
Protein Subunits/metabolism | 2 | 4.0 |
Membrane Glycoproteins/*blood | 2 | 3.0 |
Platelet Activating Factor/pharmacology | 2 | 4.0 |
*Basophil Degranulation Test | 2 | 100.0 |
Thrombosis/*blood | 2 | 7.0 |
Cytoplasmic Granules/secretion | 2 | 15.0 |
Serotonin/secretion | 2 | 8.0 |
Complement 3/metabolism | 2 | 0.0 |
*Cell Adhesion Molecules | 4 | 1.0 |
Membrane Glycoproteins/analysis | 2 | 0.0 |
Melanoma/*pathology | 2 | 3.0 |
Citric Acid | 2 | 5.0 |
Solutions | 2 | 1.0 |
P-Selectin | 10 | 18.0 |
Platelet Membrane Glycoproteins/immunology/*metabolism | 2 | 16.0 |
Neutrophils/*metabolism | 3 | 1.0 |
T-Lymphocytes/*immunology | 3 | 0.0 |
Antigens, CD/analysis/*physiology | 2 | 7.0 |
Neutrophils/immunology/*physiology | 2 | 18.0 |
Recombinant Proteins/pharmacology | 2 | 0.0 |
Up-Regulation/immunology | 2 | 1.0 |
Basophils/*metabolism | 2 | 28.0 |
Platelet Membrane Glycoproteins/blood | 2 | 66.0 |
beta-Thromboglobulin/analysis | 2 | 2.0 |
Spain | 2 | 0.0 |
Thrombosis/diagnosis | 2 | 50.0 |
Multiple Myeloma/*pathology | 2 | 3.0 |
Antigens, Surface/*genetics | 2 | 3.0 |
Receptors, Immunologic/metabolism | 2 | 1.0 |
Aspirin/*pharmacology | 3 | 6.0 |
Kidney | 3 | 0.0 |
Exons | 2 | 0.0 |
Introns | 2 | 0.0 |
Platelet Transfusion | 2 | 6.0 |
Gene Expression Regulation, Neoplastic | 2 | 0.0 |
Genetic Vectors | 2 | 0.0 |
Promoter Regions (Genetics) | 2 | 0.0 |
*Protein Biosynthesis | 2 | 0.0 |
Glycoproteins/metabolism | 2 | 1.0 |
Serum Albumin/immunology | 2 | 9.0 |
Serum Albumin/pharmacology | 2 | 5.0 |
*Ultraviolet Rays | 2 | 0.0 |
DNA, Complementary/genetics | 2 | 0.0 |
Peptide Mapping | 2 | 0.0 |
RNA, Messenger/genetics | 2 | 0.0 |
Blood Platelets/*pathology | 2 | 13.0 |
Cross-Sectional Studies | 2 | 0.0 |
Retrospective Studies | 2 | 0.0 |
Chromosome Mapping | 3 | 0.0 |
beta-Thromboglobulin/metabolism | 2 | 3.0 |
Bronchial Provocation Tests | 2 | 2.0 |
Bronchoalveolar Lavage Fluid/*cytology | 2 | 4.0 |
Receptors, Leukocyte-Adhesion/immunology | 2 | 16.0 |
B-Lymphocytes/*immunology | 2 | 0.0 |
Lymphatic Metastasis | 2 | 0.0 |
Neoplasm Metastasis | 3 | 0.0 |
DNA/genetics | 2 | 0.0 |
Sequence Homology, Nucleic Acid | 3 | 0.0 |
Glycosylation | 3 | 0.0 |
Species Specificity | 6 | 0.0 |
Diabetes Complications | 2 | 1.0 |
Diabetes Mellitus/*blood | 2 | 2.0 |
Antibodies, Anti-Idiotypic/metabolism | 2 | 28.0 |
Immunoglobulin E/*immunology | 2 | 8.0 |
Antigens, CD11 | 2 | 2.0 |
Membrane Proteins/*analysis | 2 | 2.0 |
Antigens, CD/*genetics/metabolism | 3 | 6.0 |
Platelet Membrane Glycoproteins/*genetics/metabolism | 3 | 50.0 |
Antigens, Neoplasm/*immunology | 2 | 1.0 |
Neoplasm Proteins/*immunology | 2 | 5.0 |
Antibodies, Monoclonal/*diagnostic use | 3 | 1.0 |
Blood Platelets/*drug effects/ultrastructure | 2 | 33.0 |
Plasma | 2 | 3.0 |
Severity of Illness Index | 2 | 0.0 |
Ticlopidine/analogs & derivatives/*therapeutic use | 2 | 100.0 |
Platelet Membrane Glycoproteins/biosynthesis | 2 | 28.0 |
Platelet Membrane Glycoproteins/drug effects | 2 | 100.0 |
*Protein Processing, Post-Translational | 2 | 0.0 |
Pollen/immunology | 2 | 6.0 |
Antigens, CD29/metabolism | 2 | 3.0 |
Immunosuppressive Agents/pharmacology | 2 | 1.0 |
Thymus Gland/*immunology | 2 | 3.0 |
Cell Membrane/*metabolism | 2 | 0.0 |
Immunization | 2 | 0.0 |
Single-Blind Method | 2 | 0.0 |
Basophils/*drug effects | 2 | 28.0 |
Macrophages/*virology | 2 | 3.0 |
C-Reactive Protein/metabolism | 2 | 0.0 |
Antigens, Surface | 2 | 3.0 |
